Genentech Misses Enbrel Deadline; Amgen Contract Facility Not Ready
Executive Summary
Genentech will not be reimbursed by Amgen for certain Enbrel manufacturing investments because Genentech's contract production line will not be ready on time, the company disclosed in its 2003 110-K filing
You may also be interested in...
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Amgen/Wyeth Enbrel Supplies Replenished With Rhode Island Plant Approval
Amgen and Wyeth are in a position to resume full promotion of the rheumatoid arthritis agent Enbrel following FDA approval of a new manufacturing site in Rhode Island